Harpoon Therapeutics, Inc.

Abbvie Biotherapeutics Inc.

Lynx Therapeutics, Inc.

Takeda Pharmaceutical Company Limited

Full Spectrum Genetics, Inc.

Cell Genesys, Inc.

Facet Biotech Corporation

Abbott Biotherapeutics Corp.

Other

Illumina Corporation

Pdl Biopharma, Inc.

Tcr2 Therapeutics Inc.

Robert B Dubridge

Bryan D Lemon

Richard J Austin

Jeanmarie Guenot

Sydney Brenner

Holger Wesche

Luke Evnin

Yoshiko Akamatsu

David Powers

Veronica Juan

Glenn Albrecht

Pui Seto

Anand Panchal

Maia Vinogradova

Patrick A Baeuerle

Fiona A Harding

Chad May

Qi S Wang

Vinay Bhaskar

Daniel J Capon

Raju S Kucherlapati

Steven R Williams

Debbie Law

Oliver Smithies

Beverly H Koller

Gary Greenburg

Sergei M Gryaznov

Michael C Pallas

Sarah N McCurdy

Mariona Lourdes De Rafael

Wenge Zhang

Susan Rhodes

Robert Hofmeister

Gregory Sieczkiewicz

David H Lloyd

Stephen A Sherwin

Charles M Forsyth

Mariona Lourdes Arbones De Rafael

Qi Wang

David B Powers

Charles Michael Forsyth

The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.

Constrained conditionally activated binding proteins

The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen is B7H3.

Single domain antigen binding domains that bind human Trop2

Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.

Single chain variable fragment CD3 binding proteins

Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.

Mesothelin binding proteins

Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.

Single domain serum albumin binding protein

The invention provides efficient methods for combining single-substitution libraries of nucleic acids that span and encode proteins of interest and for selecting resultant mutant proteins after expression which have improved properties or characteristics.

Method of improving characteristics of proteins

Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.

Compositions and methods for TCR reprogramming using fusion proteins

The present invention is directed to novel Anti-TNF&#x3b1; antibody binding compounds and methods of using the same. Anti-TNF&#x3b1; antibody binding compounds of the invention comprise novel heavy chain immunoglobulin polypeptides of portions thereof. In some embodiments, the invention also includes pharmaceutical compositions comprising at least one Anti-TNF&#x3b1; antibody binding compound. The invention further provides the use of an Anti-TNF&#x3b1; antibody binding compound of the invention in the preparation of a medicament for the therapeutic and/or prophylactic treatment of a disorder.

Anti-TNF&#x3b1; binding compounds and uses thereof

The invention is directed to novel antibody binding compounds specific for the human B7H3 and uses of such compounds for diagnostic and therapeutic purposes.

Anti-B7H3 binding compounds and uses thereof

Disclosed herein are PSMA binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a PSMA binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.

Prostate specific membrane antigen binding protein

Provided herein are prostate specific membrane antigen (PSMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to PSMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such PSMA targeting trispecific proteins. Also disclosed are methods of using the disclosed PSMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.

PSMA targeting trispecific proteins and methods of use

Provided herein are mesothelin (MSLN) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to MSLN. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such MSLN targeting trispecific proteins. Also disclosed are methods of using the disclosed MSLN targeting trispecific proteins in the prevention, and/or treatment of diseases, conditions and disorders.

MSLN targeting trispecific proteins and methods of use

Growing community of inventors

Belmont, CA, United States of America

Robert B Dubridge